Back in April the SMC accepted the drug for use in patients with chronic migraine.
Back in April the SMC accepted the drug for use in patients with chronic migraine.
Earlier this year, EQL launched its debut product ‘Phio’, a chatbot that thinks and acts like a physiotherapist.
Cardiovascular disease costs the NHS £7 billion a year.
The drug cut the risk of death by 27%.
There is now only 1 week left to secure a place in the 2019 Sales Awards, which will be closing for entry on Friday the 13th of September.
The approval is a “landmark decision for patients across the European Union.”
The NHS Long Term Plan states that all patients should have access to online and video consultations by 2021.
The drug is a monoclonal antibody designed to bind with a protein called PD-L1.
The combo reduced the risk of death by 47% in a clinical trial.
The NHS will recieve a cash increase of £33.9 billion a year by 2023-24 compared to 2018-19 budgets.
The licensing agreement enables the company’s “freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi”.
The news comes after Cancer Research UK found that obesity causes more cases of certain cancers than smoking.
RSV is a highly prevalent, very contagious respiratory infection and a leading cause of bronchitis and pneumonia.
The company has released a short documentary and five mini-films, outlining the symptoms that led patients to their diagnosis.
Entry for the 2019 PharmaTimes Marketer of the Year competition will be closing for entry on the 16th September.